Test Directory

• AD-Detect™ Likelihood Score Interpretation
• Quest AD-Detect™ Beta-Amyloid 42/40 Ratio
• Quest AD-Detect™ Phosphorylated tau217(p-tau217)
• AD-Detect™ Likelihood Score

Intended use is for Alzheimer's Diagnosis. Independent measurement and interpretation of plasma amyloid ratios (AB42/40) and phosphorylated tau levels (p-tau181 and p-tau217) provide clinically valuable insight into patient risk for development of Alzheimer's disease. However, by combining core AD pathological markers for a single analytical interpretation have been shown to significantly improve predictive performance and accuracy for detecting amyloid positivity and confirming a diagnosis of Alzheimer's disease. The AD-Detect™ ABeta 42/40 and p-tau217 Evaluation, Plasma evaluates a patient's plasma AB42/40 ratios and p-tau217 levels reporting out the likelihood that a symptomatic patient suspected of AD has a High, Indeterminant, or Low likelihood of amyloid pathology consistent with AD. This panel meets established performance criteria for confirming a diagnosis of Alzheimer's disease utilizing plasma biomarkers.

Specimen Type: Plasma

Collection Container: Lavender Top (EDTA)

Desired Specimen Volume: 2.5 mL (1.25 mL split into two aliquot tubes)

1. Collect 2 lavender top (EDTA) tubes via venipuncture.

1. Mix by inversion 10 times.
2. Separate plasma from cells within 1 hour of collection.
3. Transfer and split 2.5 mL of plasma into two clear aliquot tubes (screw cap).
4. There should be about 1.25 mL of plasma per aliquot tube.

Patients should be cautioned to stop biotin consumption at least 72 hours prior to collection of a sample.

Transport to the laboratory frozen.

• Moderate hemolysis
• Gross hemolysis
• Specimen collected in a glass, polystyrene, or polycarbonate tube

See patient report.

Quest Diagnostics does not perform this test for individuals under the age of 18. Pre-test and post-test counseling is strongly recommended.

• AD-Detect™ ABeta 42/40 and p-tau217 Evaluation, Plasma